Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

(HZNP)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
91.1(c) 88.2(c) 88.04(c) 86.57(c) 86.42(c) Last
2 609 600 2 153 005 1 554 474 1 362 761 2 264 052 Volume
+0.77% -3.18% -0.18% -1.67% -0.17% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 3 200 M - -
Net income 2021 542 M - -
Net Debt 2021 1 151 M - -
P/E ratio 2021 58,0x
Yield 2021 -
Sales 2022 3 963 M - -
Net income 2022 789 M - -
Net cash position 2022 134 M - -
P/E ratio 2022 21,1x
Yield 2022 -
Capitalization 19 602 M 19 602 M -
EV / Sales 2021 6,49x
EV / Sales 2022 4,91x
Nbr of Employees 1 805
Free-Float 97,8%
More Financials
Company
Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and... 
Sector
Pharmaceuticals
Calendar
03/02Earnings Release
More about the company
Ratings of Horizon Therapeutics Public Limited Company
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
01/11Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use..
AQ
01/10Horizon Therapeutics Seeks to Expand Indication for Uncontrolled Gout Medicine Krystexx..
MT
01/10Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use..
BU
01/062022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, P..
AQ
01/06Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Dev..
BU
01/06Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Dev..
CI
2021Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
BU
2021Horizon Therapeutics Working With Alpine Immune Sciences to Develop Therapies for Autoi..
MT
2021HORIZON THERAPEUTICS PUBLIC LTD CO : Regulation FD Disclosure (form 8-K)
AQ
2021Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Coll..
BU
2021Alpine Immune Sciences, Inc. announced that it expects to receive $15 million in fundin..
CI
2021Wells Fargo Starts Horizon Therapeutics at Overweight With $137 Price Target
MT
2021INSIDER SELL : Horizon Therapeutics Public Ltd
MT
2021Horizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to..
AQ
2021Horizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to..
BU
More news
News in other languages on HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
01/10Horizon Therapeutics cherche à étendre l'indication du médicament contre la goutte non ..
01/06Horizon Therapeutics plc annonce une expansion significative de ses capacités de recher..
2021Horizon Therapeutics collabore avec Alpine Immune Sciences pour développer des thérapie..
2021Horizon Therapeutics affirme que les données de phase 2/3 confirment l'efficacité d'Upl..
2021Horizon Therapeutics déclare que les données montrent un " taux élevé d'adhésion des pa..
More news
Analyst Recommendations on HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
More recommendations
Chart HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Duration : Period :
Horizon Therapeutics Public Limited Company Technical Analysis Chart | HZNP | IE00BQPVQZ61 | MarketScreener
Technical analysis trends HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 86,42 $
Average target price 141,33 $
Spread / Average Target 63,5%
EPS Revisions
Managers and Directors
Timothy P. Walbert Chairman, President & Chief Executive Officer
Paul W. Hoelscher Chief Financial Officer & Executive Vice President
Jeffrey W. Sherman CMO, Executive VP-Development & Regulatory Affairs
Jeffrey D. Kent Executive VP-Medical Affairs & Outcomes Research
Karin Rosen Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY-19.66%19 636
JOHNSON & JOHNSON-3.40%435 037
ROCHE HOLDING AG-3.69%322 260
PFIZER, INC.-8.47%303 375
ABBVIE INC.-1.75%235 181
NOVO NORDISK A/S-13.40%220 833